EA200501710A1 - Замещённые карбоновые кислоты - Google Patents

Замещённые карбоновые кислоты

Info

Publication number
EA200501710A1
EA200501710A1 EA200501710A EA200501710A EA200501710A1 EA 200501710 A1 EA200501710 A1 EA 200501710A1 EA 200501710 A EA200501710 A EA 200501710A EA 200501710 A EA200501710 A EA 200501710A EA 200501710 A1 EA200501710 A1 EA 200501710A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
substituted carbon
applicable
treatment
carbon acids
Prior art date
Application number
EA200501710A
Other languages
English (en)
Inventor
Майкл К. Ван Зандт
Даррен Уайтхаус
Керри Коумз
Шаоцзинь Ху
Original Assignee
ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи filed Critical ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи
Publication of EA200501710A1 publication Critical patent/EA200501710A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Настоящее изобретение относится к соединениям и фармацевтически приемлемым солям формулы (I), которые используют в лечении метаболических расстройств, связанных с инсулинорезистентностью или гиперликемией. Указанные соединения включают ингибиторы протеинтирозинфосфатазы (РТР-1В), которые применимы для лечения диабета и других медиированных РТВ-1В заболеваний и им подобных. Соединения по изобретению также применимы в фармацевтических композициях и способах лечения вышеупомянутых состояний.
EA200501710A 2003-04-30 2004-04-14 Замещённые карбоновые кислоты EA200501710A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46705703P 2003-04-30 2003-04-30
PCT/US2004/011371 WO2004099168A2 (en) 2003-04-30 2004-04-14 Substituted carboxylic acids

Publications (1)

Publication Number Publication Date
EA200501710A1 true EA200501710A1 (ru) 2006-06-30

Family

ID=33435014

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501710A EA200501710A1 (ru) 2003-04-30 2004-04-14 Замещённые карбоновые кислоты

Country Status (13)

Country Link
US (2) US7358364B2 (ru)
EP (1) EP1620420A2 (ru)
JP (1) JP2006525329A (ru)
KR (1) KR20060006953A (ru)
CN (1) CN1812977A (ru)
AU (1) AU2004236173B2 (ru)
BR (1) BRPI0409914A (ru)
CA (1) CA2523714A1 (ru)
EA (1) EA200501710A1 (ru)
MX (1) MXPA05011524A (ru)
NO (1) NO20054957L (ru)
WO (1) WO2004099168A2 (ru)
ZA (1) ZA200509631B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358364B2 (en) 2003-04-30 2008-04-15 The Institute For Pharmaceutical Discovery Llc Substituted carboxylic acids
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
FR2869615B1 (fr) * 2004-05-03 2007-11-16 Merck Sante Soc Par Actions Si Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000762A (es) 2004-07-22 2007-04-02 Ptc Therapeutics Inc Tienopiridinas para tratamientode hepatitis c.
AU2005302409A1 (en) * 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery Llc Substituted carboxylic acids
JP2008520692A (ja) * 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環置換カルボン酸
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
AU2007231547B2 (en) 2006-03-29 2012-07-12 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
KR20100101130A (ko) 2007-12-07 2010-09-16 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
CA2707494C (en) 2007-12-07 2018-04-24 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ602030A (en) 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
PT2651915T (pt) 2010-12-17 2016-07-14 Mitsubishi Tanabe Pharma Corp Composto aricíclico contínuo
WO2013187496A1 (ja) 2012-06-15 2013-12-19 田辺三菱製薬株式会社 芳香族複素環化合物
US9895330B2 (en) 2013-07-11 2018-02-20 Bristol-Myers Squibb Company IDO inhibitors
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
WO2015150350A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
EP3247770B1 (de) * 2015-01-20 2019-04-10 cynora GmbH Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1176339A (en) * 1965-12-27 1970-01-01 Lilly Co Eli Hydrocinnamic Acid Compounds and Processes for making them
IL30498A0 (en) 1967-08-14 1968-10-24 Merck & Co Inc Process for the preparation of phenyl salicylic acid compounds and intermediates used therein
CH501575A (de) * 1967-10-06 1971-01-15 Ciba Geigy Ag Verfahren zur Herstellung einer neuen Aryloxyalkansäure und ihrer Salze
CH499526A (de) * 1968-06-06 1970-11-30 Ciba Geigy Ag Verfahren zur Herstellung von neuen Tetrazolderivaten
US3755603A (en) * 1970-07-01 1973-08-28 Syntex Corp Biphenylyloxyacetic acids in pharmaceutical compositions
DE2205732A1 (de) * 1972-02-08 1973-08-16 Thomae Gmbh Dr K Neue 4-(4-biphenylyl)-butensaeurederivate
NL7301246A (ru) * 1972-02-14 1973-08-16
DE2358789A1 (de) * 1973-02-07 1975-06-05 Merck Patent Gmbh Hydratropasaeure-derivate und verfahren zu ihrer herstellung
FR2457275A1 (fr) 1979-05-21 1980-12-19 Fabre Sa Pierre Acides p-biphenyl-4 methyl-2 buten-3 oiques utiles dans le traitement des rhumatismes
TW268952B (ru) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
ATE359264T1 (de) 1996-01-23 2007-05-15 Shionogi & Co Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
DE69739003D1 (de) 1996-04-12 2008-10-30 Searle Llc Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren
WO1997039748A1 (en) * 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
AU8750298A (en) 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
CO5011105A1 (es) 1997-12-22 2001-02-28 Novartis Ag Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion
AU2713699A (en) 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
YU59600A (sh) * 1998-03-31 2002-12-10 The Institute For Pharmaceutical Discovery Inc. Supstituisane indolalkanoidske kiseline
US6232322B1 (en) * 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6221902B1 (en) * 1998-05-12 2001-04-24 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
AU4072799A (en) * 1998-05-12 1999-12-13 American Home Products Corporation 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
CN1308620A (zh) 1998-05-12 2001-08-15 美国家用产品公司 用于治疗胰岛素抗性和高血糖的联苯基磺酰基芳基羧酸
CA2330557A1 (en) * 1998-05-12 1999-11-18 Robert Emmett Mcdevitt Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
AU3791899A (en) 1998-05-12 1999-11-29 American Home Products Corporation (2-acylaminothiazole-4-yl)acetic acid derivatives
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
HUP0202384A3 (en) * 1999-06-25 2003-03-28 Inst For Pharm Discovery Inc Substituted phenoxyacetic acids
WO2001070754A1 (en) * 2000-03-22 2001-09-27 Merck Frosst Canada & Co. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
AU2001248765A1 (en) 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
AU4882101A (en) 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
WO2001083461A1 (fr) 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Derives de thiazole et d'oxazole
WO2002004459A1 (en) 2000-07-07 2002-01-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
ATE362468T1 (de) 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
US6472545B2 (en) * 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
AU2001292285A1 (en) 2000-09-29 2002-04-15 Shionogi And Co., Ltd. Thiazole or oxazole derivatives
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
CN100344616C (zh) 2001-06-12 2007-10-24 维尔斯达医疗公司 用于治疗代谢失调的化合物
DE10150172A1 (de) 2001-10-11 2003-04-30 Morphochem Ag Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren
JP4219810B2 (ja) 2001-10-26 2009-02-04 塩野義製薬株式会社 Ｍｍｐ阻害作用を有するスルホンアミド誘導体
CA2469228A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
AU2003256911B2 (en) 2002-07-30 2008-07-10 Merck Sharp & Dohme Corp. PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
BRPI0409447A (pt) 2003-04-14 2006-04-18 Inst For Pharm Discovery Inc ácidos fenilalcanóicos substituìdos
US7358364B2 (en) 2003-04-30 2008-04-15 The Institute For Pharmaceutical Discovery Llc Substituted carboxylic acids
EP1704856A4 (en) 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
WO2006050097A1 (en) 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery, Llc Substituted phenylalkanoic acids

Also Published As

Publication number Publication date
NO20054957L (no) 2006-01-23
MXPA05011524A (es) 2006-03-21
KR20060006953A (ko) 2006-01-20
JP2006525329A (ja) 2006-11-09
ZA200509631B (en) 2007-02-28
WO2004099168A2 (en) 2004-11-18
US20040266788A1 (en) 2004-12-30
CA2523714A1 (en) 2004-11-18
WO2004099168A3 (en) 2005-02-24
US7358364B2 (en) 2008-04-15
CN1812977A (zh) 2006-08-02
BRPI0409914A (pt) 2006-04-25
NO20054957D0 (no) 2005-10-25
AU2004236173B2 (en) 2008-07-03
US20090082392A1 (en) 2009-03-26
EP1620420A2 (en) 2006-02-01
AU2004236173A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
EA200501710A1 (ru) Замещённые карбоновые кислоты
EA200501607A1 (ru) Замещённые фенилалкановые кислоты
TW200630327A (en) Substituted phenylalkanoic acids
EA200501715A1 (ru) Замещённые аминокарбоновые кислоты в качестве ингибиторов протеинтирозинфосфатазы-1в
MXPA05011539A (es) Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
EA200501713A1 (ru) Фенилзамещённые карбоновые кислоты
TW200630354A (en) Substituted amino carboxylic acids
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
WO2006055708A3 (en) Heterocycle substituted carboxylic acids for the treatment of diabetes
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
DE602004017174D1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
CY1115940T1 (el) Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
MX2009004362A (es) Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk.
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
TW200631949A (en) Substituted carboxylic acids
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE473737T1 (de) Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
EA200600318A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)